t
GlaxoSmithKline plc announced that its Chief Executive Officer, Ms E Walmsley, along with nine other Persons Discharging Managerial Responsibilities (PDMRs) and one person closely associated (PCA), acquired Ordinary Shares on April 11, 2022. Each individual acquired 14 Ordinary Shares under the Company's Share Reward Plan at a price of £17.7876 per share via the London Stock Exchange.
| Date | 13 Apr 2022 |
| Time | 17:11:56 |
| Category | Director/PDMR dealings |
| ID | 3272I |
GlaxoSmithKline plc (the 'Company')
Transaction notification
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Ms E Walmsley |
|||
|
b) |
Position/status |
Chief Executive Officer |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.7876 |
7 (partnership shares) |
|
||
|
|
£17.7876 |
7 (matching shares) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
14 Ordinary Shares £17.7876 |
||||
|
e) |
Date of the transaction |
2022-04-11 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr R Connor |
|||
|
b) |
Position/status |
President, Vaccines and Global Health |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.7876 |
7 (partnership shares) |
|
||
|
|
£17.7876 |
7 (matching shares) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
14 Ordinary Shares £17.7876 |
||||
|
e) |
Date of the transaction |
2022-04-11 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Ms D Conrad |
|||
|
b) |
Position/status |
Chief People Officer |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.7876 |
7 (partnership shares) |
|
||
|
|
£17.7876 |
7 (matching shares) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
14 Ordinary Shares £17.7876 |
||||
|
e) |
Date of the transaction |
2022-04-11 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr J Ford |
|||
|
b) |
Position/status |
SVP and Group General Counsel, Legal and Compliance |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.7876 |
7 (partnership shares) |
|
||
|
|
£17.7876 |
7 (matching shares) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
14 Ordinary Shares £17.7876 |
||||
|
e) |
Date of the transaction |
2022-04-11 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Ms S Jackson |
|||
|
b) |
Position/status |
SVP, Global Communications and CEO Office |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.7876 |
7 (partnership shares) |
|
||
|
|
£17.7876 |
7 (matching shares) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
14 Ordinary Shares £17.7876 |
||||
|
e) |
Date of the transaction |
2022-04-11 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr D Jackson |
|||
|
b) |
Position/status |
PCA of Ms S Jackson (SVP, Global Communications and CEO Office) |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.7876 |
7 (partnership shares) |
|
||
|
|
£17.7876 |
7 (matching shares) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
14 Ordinary Shares £17.7876 |
||||
|
e) |
Date of the transaction |
2022-04-11 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr D Redfern |
|||
|
b) |
Position/status |
Chief Strategy Officer |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.7876 |
7 (partnership shares) |
|
||
|
|
£17.7876 |
7 (matching shares) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
14 Ordinary Shares £17.7876 |
||||
|
e) |
Date of the transaction |
2022-04-11 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr R Simard |
|||
|
b) |
Position/status |
President, Pharmaceuticals Supply Chain |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.7876 |
7 (partnership shares) |
|
||
|
|
£17.7876 |
7 (matching shares) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
14 Ordinary Shares £17.7876 |
||||
|
e) |
Date of the transaction |
2022-04-11 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr P Thomson |
|||
|
b) |
Position/status |
President, Global Affairs |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.7876 |
7 (partnership shares) |
|
||
|
|
£17.7876 |
7 (matching shares) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
14 Ordinary Shares £17.7876 |
||||
|
e) |
Date of the transaction |
2022-04-11 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Ms D Waterhouse |
|||
|
b) |
Position/status |
CEO, ViiV Healthcare |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.7876 |
7 (partnership shares) |
|
||
|
|
£17.7876 |
7 (matching shares) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
14 Ordinary Shares £17.7876 |
||||
|
e) |
Date of the transaction |
2022-04-11 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Ms V Whyte |
|||
|
b) |
Position/status |
Company Secretary |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.7876 |
7 (partnership shares) |
|
||
|
|
£17.7876 |
7 (matching shares) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
14 Ordinary Shares £17.7876 |
||||
|
e) |
Date of the transaction |
2022-04-11 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||